GENFIT CORP.
245 First Street - 18th Floor
Suite 1806
Cambridge
Massachusetts
02142
United States
Tel: 617-444-8416
Fax: 617- 444-8405
Website: http://www.genfit.com/
Email: Karen.Miller@Genfit.com
About GENFIT CORP.
Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.
Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.
Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.
GENFIT
Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
59120 Loos
France
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001
224 articles about GENFIT CORP.
-
GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology
9/26/2023
GENFIT announced the publication of data demonstrating the effectiveness of its non-alcoholic steatohepatitis diagnostic technology NIS4® by the FNIH’s NIMBLE project in the scientific journal, Nature Medicine.
-
GENFIT to Participate in Upcoming September 2023 Investor Conferences
9/5/2023
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, announced that it will participate in the following upcoming investor conferences.
-
The companies Friday reported positive late-stage results for elafibranor as a second-line treatment for primary biliary cholangitis, a rare liver disease.
-
GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset
5/31/2023
GENFIT announced it has licensed the exclusive worldwide rights of ASK1 Inhibitor SRT-015 from Seal Rock Therapeutics, a Seattle, Washington based clinical stage company developing first-in-class and best-in-class kinase inhibitors.
-
GENFIT: May 24, 2023 Combined Shareholders Meeting results
5/24/2023
GENFIT announced the results of the Combined Shareholders Meeting which took place on May 24, 2023.
-
GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology
5/23/2023
GENFIT announced the publication of the development and validation of NIS2+™ in the Journal of Hepatology.
-
GENFIT Reports First Quarter 2023 Financial Information
5/11/2023
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, announced its cash position as of March 31, 2023 and revenues for the first three months of 20231.
-
GENFIT Announces Publication of Extra-Financial Performance Report 2022
4/27/2023
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, announced the publication of its Extra-Financial Performance Report 2022.
-
GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents
4/19/2023
GENFIT announced that it published in the April 19, 2023 French legal announcements bulletin n°47 its convening notice that the Combined Shareholders Meeting will be held on May 24, 2023, at 10:00am, at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.
-
GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F
4/18/2023
GENFIT announced the filing of its 2022 Universal Registration Document with the Autorité des marchés financiers and its Annual Report on Form 20-F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission.
-
GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update
4/13/2023
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs, announced annual financial results for the year ended December 31, 2022.
-
GENFIT Announces Revenues and Cash Position as of December 31, 2022
2/28/2023
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, announced its cash position as of December 31, 2022 and revenues for 2022.
-
GENFIT Announces 2023 Financial Calendar
1/24/2023
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, announced its provisional financial calendar for 2023.
-
GENFIT to Participate in Upcoming Investor Conferences - Jan 05, 2023
1/5/2023
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, announced that management will participate in upcoming investor conferences.
-
GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases
11/17/2022
GENFIT announced the highlights from its Pipeline Day events reviewing the Company’s clinical progress and recent strategic updates.
-
GENFIT Reports Third Quarter 2022 Financial Information
11/10/2022
GENFIT announced its cash position as of September 30, 2022 and revenue for the first nine months of 20221.
-
GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis
9/29/2022
GENFIT announced the signing of the Share Purchase Agreement and the completion of its acquisition of Versantis AG under the terms announced in its press release on September 19, 2022.
-
GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update
9/28/2022
GENFIT announced its first half-year 2022 financial results and provided a corporate update.
-
GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases
9/19/2022
GENFIT announced it has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases.
-
Genfit announced that it is Versantis for roughly $40 million cash and approximately $65 million in milestone payments and other considerations.